Supernus Pharmaceuticals, Inc. (SUPN) is a publicly traded Healthcare sector company. As of May 21, 2026, SUPN trades at $48.47 with a market cap of $2.81B and a P/E ratio of -96.00. SUPN moved +2.27% today. Year to date, SUPN is -1.44%; over the trailing twelve months it is +46.66%. Its 52-week range spans $29.16 to $59.68. Analyst consensus is strong buy with an average price target of $63.17. Rallies surfaces SUPN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Supernus Pharmaceuticals, Inc. (SUPN) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. SUPN moved +2.27% today. Analyst consensus is strong buy.
| Metric | Value |
|---|---|
| Price | $48.47 |
| Market Cap | $2.81B |
| P/E Ratio | -96.00 |
| EPS | $-0.51 |
| Dividend Yield | 0.00% |
| 52-Week High | $59.68 |
| 52-Week Low | $29.16 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $776.83M |
| Net Income | $-29.02M |
| Gross Margin | 89.42% |
6 analysts cover SUPN: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $63.17.